Taro Inks $36M Investor Deal Over Generics Price-Fixing
Taro Pharmaceutical Industries shareholders asked a New York federal judge Monday to greenlight a $36 million settlement resolving proposed class claims that the company misled investors about alleged generic drug price-fixing...To view the full article, register now.
Already a subscriber? Click here to view full article